Latest JRS Pharma News

Brittany, France - JRS PHARMA is Pleased to Announce the Worldwide Availability of the VIVAPHARM® Alginates Product Line.

JRS PHARMA is pleased to announce that the Rettenmaier Natural Fiber Manufacturing facilities in Changzhou, China, were awarded an EXCiPACT™ Certificate for Good Manufacturing Practices (GMP).

JRS PHARMA Statement on the Coronavirus Pandemic

On 31th October 2018, JRS Marine Products Landerneau became part of the JRS family. Located on the west coast of France, the state-of-the-art facility is totally dedicated to the production and developement of natural based European alginates for pharmaceutical and food applications.

The agreement provides for the entry of the German group into the capital of the Silvateam Food Ingredients.

JRS PHARMA is pleased to announce cDMF filings with the NMPA for many of their excipient products for use in China.

JRS PHARMA is pleased to announce that the JRS Pharma site in Weißenborn, Germany was awarded an EXCiPACT Certificate from DQS for the production of Microcrystalline Cellulose and Silicified Microcrystalline Cellulose as well as Good Distribution Practice for the central logistic warehouse.

JRS PHARMA is pleased to announce that the JRS Pharma & Gujarat Microwax Private Limited sites producing Microcrystalline Cellulose and Superdisintegrants were awarded an EXCiPACT Certificate from SGS.

JRS Group was approved by the European Commission (EC) as a suitable purchaser of the legacy DuPont N&H alginates business. The acquisition is expected to close in Q32018.

JRS PHARMA is pleased to announce that PROSOLV® SMCC (Silicified Microcrystalline Cellulose) is now monographed with the Japanese Pharmaceutical Excipients (JPE), joining the rest of JRS PHARMA’s complete portfolio of excipients solutions available in Japan.